These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27920239)

  • 1. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
    Townsend B
    Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
    Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
    Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam.
    Moir HVJ; Tenni B; Gleeson D; Lopert R
    Glob Public Health; 2018 Apr; 13(4):400-413. PubMed ID: 27841097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new generation of trade policy: potential risks to diet-related health from the trans pacific partnership agreement.
    Friel S; Gleeson D; Thow AM; Labonte R; Stuckler D; Kay A; Snowdon W
    Global Health; 2013 Oct; 9():46. PubMed ID: 24131595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.
    Labonté R; Crosbie E; Gleeson D; McNamara C
    Global Health; 2019 May; 15(1):35. PubMed ID: 31088499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trans-Pacific Partnership and pharmaceutical innovation.
    Freeman RA
    Res Social Adm Pharm; 2016; 12(4):633-7. PubMed ID: 26803645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of bilateral free trade agreements on access to medicines.
    Correa CM
    Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Trans-Pacific Partnership Agreement: Trading away our health?
    Ruckert A; Schram A; Labonté R
    Can J Public Health; 2015 Apr; 106(4):e249-51. PubMed ID: 26285198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
    Luo J; Kesselheim AS
    AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia.
    Lexchin J; Gleeson D
    Int J Health Serv; 2016 Oct; 46(4):597-613. PubMed ID: 27516183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.